Pmda - Pharmaceuticals and Medical Devices Agency

Jump to body

Navigation of each product type

Our recommended contents

Navigation of each product type

Our recommended contents

Here begins the text.

Post-marketing Safety Measures

Click here for detail

Scientific Research and Analyses

Information Services

Regulatory Information

What's newBack number

　　All

October 22, 2021PMDA Risk Communication: Atezolizumab (genetical recombination) posted
October 15, 2021Revisions of PRECAUTIONS: Coronavirus modified uridine RNA vaccine (SARS-CoV-2)(Comirnaty intramuscular injection) etc. posted

Pmda - Pharmaceuticals and Medical Devices Agency

JCN 3010005007409

Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki,
Chiyoda-ku, Tokyo 100-0013 Japan

Copyright (C) Pharmaceuticals and Medical Devices Agency, All Rights Reserved.